Ixico Regulatory News (IXI)

15 Nov 2005 07:02

Phytopharm PLC15 November 2005 Company Contact: U.K. Investor relations contactPhytopharm, plc Financial DynamicsRichard Dixey David Yates/Ben Atwell+44 7867 782000 +44 207 831 3113www.phytopharm.com PHYTOPHARM PLC Clinical trial results GODMANCHESTER, Cambridgeshire, U.K. (15 November, 2005) - Phytopharm plc (LSE:PYM; NASDAQBB: PHYOF; PHYOY) ("Phytopharm") has become aware of rumourscirculating that the results of the phase II double blind placebo controlledstudy on CoganeTM, Phytopharm's treatment for mild to moderate Alzheimer'sdisease, are known to the Company. Following advice received from the London Stock Exchange, Phytopharm wishes tomake clear that it has no such information, and that the preliminary results ofthis study will not be available to the Company until early December 2005, atwhich time they will be promptly announced to the stock market. - Ends - This information is provided by RNS The company news service from the London Stock Exchange